Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2012
Filing Date: March 8, 2013
Accounting Basis: International Financial Reporting Standards (IFRS)
Outstanding Shares: 5,397,595,969 Ordinary Shares (25 pence par value)
GSK operates in three primary business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company is a large accelerated filer and a well-known seasoned issuer. The financial statements have been audited by PricewaterhouseCoopers LLP.
Key Financial Metrics (Year Ended Dec 31, 2012)
| Metric | Core Results (£m) | Total Results (£m) |
|---|---|---|
| Gross Profit | 19,353 | 18,537 |
| Operating Profit | 8,330 | 7,392 |
| Profit Before Taxation | 7,635 | 6,692 |
| Profit After Taxation | 5,771 | 4,744 |
| Earnings Per Share (EPS) | 112.7p | 92.9p |
| Weighted Average Shares (m) | 4,912 | 4,912 |
Significant Adjustments to Total Results:
- Intangible Amortisation: £477m
- Intangible Impairment: £693m
- Major Restructuring: £557m
- Legal Costs: £436m
- Other Operating Income: £1,254m
Liquidity and Receivables:
Trade receivables due from the three largest US wholesalers totaled £815 million as of December 31, 2012. The filing incorporates by reference detailed cash flow and liquidity data from the GSK Annual Report 2012 but does not explicitly state total cash flow or debt figures in the provided text.
Material Changes vs. Prior Period (2011)
Profitability Trends:
- Total Profit After Taxation: Decreased from £5,458m in 2011 to £4,744m in 2012.
- Total EPS: Decreased from 104.6p in 2011 to 92.9p in 2012.
- Core Profit After Taxation: Decreased from £6,007m in 2011 to £5,771m in 2012.
Key Drivers of Change:
- Legal Settlements: In 2012, GSK entered into a settlement agreement with the US federal government resulting in a payment of US$3 billion. This significantly impacted legal costs and provisions.
- Restructuring: Major restructuring costs increased from £590m in 2011 to £557m in 2012 (Total Results), though core restructuring activity varied.
- Impairment: Intangible impairment charges were significantly higher in 2012 (£693m) compared to 2011 (£109m).
- Other Operating Income: A significant positive adjustment of £1,254m in 2012 (vs. £301m in 2011) partially offset other negative adjustments.
Guidance, Risks, and Contingencies
Management Commentary and Outlook:
The filing incorporates the "CEO's review" and "Financial review 2012" from the Annual Report. Management highlighted the impact of the US legal settlement and the ongoing need to replace sales of older products as patents expire. The company continues to focus on R&D to deliver new products and simplify its operating model.
Principal Risk Factors:
- Patent Expiry and Generic Competition: Significant risk of sales erosion as patents expire, particularly for products like Seretide/Advair. Generic competition in the USA and Europe is a primary threat to margins.
- Legal and Regulatory: Ongoing exposure to product liability litigation, anti-trust claims, and government investigations. The US$3 billion settlement in 2012 is a material example of this risk.
- Pricing and Reimbursement: Increasing pressure on pricing in major markets (USA, Europe) due to healthcare budget constraints and government intervention.
- Product Quality and Supply: Risks related to compliance with Good Manufacturing Practice (cGMP) and potential supply chain disruptions.
- Geopolitical and Economic: Exposure to economic instability in Europe and regulatory risks in emerging markets. Specific disclosure notes sales to Iran totaling £19.7m gross revenue in 2012, with the company ceasing Consumer Healthcare sales to the region.
Contingencies:
The company has made provisions related to legal proceedings and investigations. Future provisions may be required, which would reduce earnings. The outcome of patent litigation and regulatory approvals for new products remains uncertain.
Investor Verification Checklist
- Legal Settlement Impact: Verify the full financial impact and future liability implications of the US$3 billion US federal government settlement.
- Patent Cliff Timeline: Review the specific expiration dates for major products (e.g., Seretide/Advair) and the status of "follow-on" product approvals in the US and Europe.
- Core vs. Reported Metrics: Analyze the reconciliation between "Core" and "Total" results to understand the sustainability of earnings excluding one-off items like impairments and restructuring.
- Iranian Sales Compliance: Confirm the status of the company's compliance with US sanctions regarding the £19.7m in sales to Iran and the cessation of Consumer Healthcare sales.
- Wholesaler Concentration: Assess the credit risk associated with the three largest US wholesalers, who accounted for 81% of US Pharmaceuticals and Vaccines turnover.
- R&D Pipeline Progress: Evaluate the late-stage pipeline summary to gauge the ability to replace revenue from expiring patents.